D-0124-2024 Class II Ongoing
FDA drug recall D-0124-2024 was initiated by Glenmark Pharmaceuticals Inc., USA on Nov 7, 2023 and is designated Class II. Reason for recall: Labeling: Label Mix-Up-Indomethacin bottles may be labeled as Naproxen The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 6, 2023
- Initiation Date
- Nov 7, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Naproxen Tablets, USP 250mg, 100-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bardez, Goa 403513, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 68462-188-01.
Reason for recall
Labeling: Label Mix-Up-Indomethacin bottles may be labeled as Naproxen
Distribution pattern
Nationwide
Code information
Lot# 19231903; Exp 4/2025 Lot# 19231858; Exp 4/2025 Lot# 19231881; Exp 4/2025 Lot# 19233484: Exp 8/2025 Lot# 19233490; Exp 8/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0124-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026